145 related articles for article (PubMed ID: 20232803)
21. Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
Bergeron RJ; Wiegand J; McManis JS; Bussenius J; Smith RE; Weimar WR
J Med Chem; 2003 Apr; 46(8):1470-7. PubMed ID: 12672247
[TBL] [Abstract][Full Text] [Related]
22. Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.
Bergeron RJ; Wiegand J; Weimar WR; McManis JS; Smith RE; Abboud KA
Chirality; 2003 Aug; 15(7):593-9. PubMed ID: 12840823
[TBL] [Abstract][Full Text] [Related]
23. Desferrithiocin: a search for clinically effective iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
[TBL] [Abstract][Full Text] [Related]
24. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
25. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
27. A comparative evaluation of iron clearance models.
Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
[TBL] [Abstract][Full Text] [Related]
28. Metabolically programmed iron chelators.
Bergeron RJ; Bharti N; McManis JS; Wiegand J
Bioorg Med Chem; 2015 Sep; 23(17):5954-71. PubMed ID: 26231739
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
Bergeron RJ; Wiegand J; Wollenweber M; McManis JS; Algee SE; Ratliff-Thompson K
J Med Chem; 1996 Apr; 39(8):1575-81. PubMed ID: 8648596
[TBL] [Abstract][Full Text] [Related]
30. Polyamine-vectored iron chelators: the role of charge.
Bergeron RJ; Bharti N; Wiegand J; McManis JS; Yao H; Prokai L
J Med Chem; 2005 Jun; 48(12):4120-37. PubMed ID: 15943485
[TBL] [Abstract][Full Text] [Related]
31. The design of orally active iron chelators.
Hider RC; Zhou T
Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
[TBL] [Abstract][Full Text] [Related]
32. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
Stahel E; Mazier D; Guillouzo A; Miltgen F; Landau I; Mellouk S; Beaudoin RL; Langlois P; Gentilini M
Am J Trop Med Hyg; 1988 Sep; 39(3):236-40. PubMed ID: 3052118
[TBL] [Abstract][Full Text] [Related]
33. Scaffold Based Search on the Desferithiocin Archetype.
Shyam M; Dev A; Sinha BN; Jayaprakash V
Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
[TBL] [Abstract][Full Text] [Related]
34. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
35. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Kicic A; Chua AC; Baker E
Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
[TBL] [Abstract][Full Text] [Related]
36. A non-human primate model for the study of oral iron chelators.
Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
[TBL] [Abstract][Full Text] [Related]
37. The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Bierer BE; Nathan DG
Blood; 1990 Nov; 76(10):2052-9. PubMed ID: 2242426
[TBL] [Abstract][Full Text] [Related]
38. Desferrithiocin.
Wolfe LC
Semin Hematol; 1990 Apr; 27(2):117-20. PubMed ID: 2349483
[No Abstract] [Full Text] [Related]
39. Deferitazole, a new orally active iron chelator.
Hider RC; Kong X; Abbate V; Harland R; Conlon K; Luker T
Dalton Trans; 2015 Mar; 44(11):5197-204. PubMed ID: 25687725
[TBL] [Abstract][Full Text] [Related]
40. An investigation of desferrithiocin metabolism.
Bergeron RJ; Wollenweber M; Wiegand J
J Med Chem; 1994 Sep; 37(18):2889-95. PubMed ID: 8071936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
